Workflow
圣诺生物等药企动态:净利润预增、收购及新药进展
He Xun Cai Jing·2025-06-20 02:08

Group 1 - The core viewpoint of the article highlights significant financial projections and strategic developments within the biopharmaceutical industry, particularly focusing on companies like Shengnuo Bio, Shanghai Laishi, and Beijing Saiseng Pharmaceutical [1] Group 2 - Shengnuo Bio anticipates a substantial increase in net profit for the first half of 2025, projecting between 77.03 million to 94.14 million yuan, representing a year-on-year increase of 253.54% to 332.10% [1] - Shanghai Laishi has announced a 4.2 billion yuan acquisition of 100% equity in Nanyue Bio, with potential additional payments based on the company's plasma collection volume, indicating a strategic move to enhance its "plasma" strategy [1] - Beijing Saiseng Pharmaceutical signed a technology transfer contract with its affiliate, Beijing BGI Protein Research Center, for the NeoAB33 new drug project, which may optimize asset structure and support further R&D funding [1] Group 3 - The CDE has accepted the application for the new indication of Eli Lilly's Pirtobrutinib tablets, which is expected to strengthen its market position in the treatment of B-cell malignancies [1] - Innovent Biologics' CLDN-18.2 ADC product IBI343 is proposed to be included as a breakthrough therapy for advanced or metastatic pancreatic cancer, marking a significant advancement in treatment options for this indication [1]